Keeping You Updated
PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
OXFORD, England, September 10 /PRNewswire/ -- PharmaVentures announced today the appointment of Nikki Watkins as Head of the Product & Portfolio Strategy Practice of Corporate Advisory, leading a team of Senior Advisors and Analysts.
Fintan Walton, PhD, PharmaVentures' Chief Executive Officer says, "We are delighted to welcome Nikki to PharmaVentures. Our Corporate Advisory business is currently undergoing exciting developments, and extensive knowledge of portfolio assessment and strategy from GSK and PricewaterhouseCoopers will be a key contributor to our growth plans."
Tibor Papp, PhD, Head of Corporate Advisory Ltd, says, "Nikki brings substantial industry and advisory experience into PharmaVentures. She will take on a leadership role, further developing our practice in strategic analysis of products, companies and markets. With Nikki's experience, PharmaVentures further strengthens its leading position as shapers of the industry."
Nikki has an honours degree in Pharmacology from Cambridge University. Most recently, she was the Director of Portfolio Consolidation & Analysis, Global Product Strategy, R&D at GlaxoSmithKline (GSK).
Nikki brings additional industry experience to PharmaVentures from various previous roles in GSK R&D, commercial analysis, portfolio management and global internal audit. Prior to this, she qualified as a Chartered Accountant at PricewaterhouseCoopers.
- ends -
Note to Editors
PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).
Now in its 18th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.